CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.
May 14th 2020
Amid the COVID-19 pandemic, the Bladder Cancer Advocacy Network is honoring Bladder Cancer Awareness Month in a slightly different way from previous years.
April 22nd 2020
The Food and Drug Administration’s approval of Jelmyto (mitomycin gel]) in low-grade upper tract urothelial cancer offers patients a much-needed treatment option, according to one expert.
April 17th 2020
Data from the phase 1b/2 trial of Padcev in combination with Keytruda displayed promise for patients with metastatic urothelial carcinoma, but further research is needed.
April 15th 2020
The Food and Drug Administration approved Jelmyto to treat patients with low-grade upper tract urothelial cancer.
April 14th 2020
Immunotherapy and targeted therapy medications have brought new hope to patients with advanced disease.
April 10th 2020
Using immunotherapy earlier, immediately after the conclusion of chemotherapy to treat metastatic bladder cancer, can delay the time until disease progression.
April 2nd 2020
A new study links e-cigarette use to bladder cancer but experts say more research is needed.
March 17th 2020
There are a number of treatment options available for patients with urothelial cancer, however, experts want to refine the current treatment paradigm amid new drugs entering the landscape.
February 23rd 2020
Treatment for patients with bladder cancer is moving away from VEGF-targeted therapies toward immune checkpoint inhibition, according to one expert.
February 20th 2020
The results of a phase 2 study looking at Padcev and Keytruda combination therapy for patients with metastatic urothelial cancer shows promise with a 73% response that did not differ for a patient’s PDL1 status.
February 16th 2020
The combination of Padcev plus Keytruda induced a high rate of durable objective response rates in patients with locally advanced or metastatic urothelial cancer.
February 5th 2020
A new study supported the use of a blood test to detect clusters of cancer cells in the blood of asymptomatic individuals, meaning, patients could have a non-invasive screening and testing method.
January 29th 2020
Better response rates may be seen in patients with advanced bladder cancer when two therapies are combined.
January 16th 2020
The Bladder Cancer Advocacy Network announces it's Bladder Cancer Research Innovation Award.
January 14th 2020
FDA has given an accelerated approval to Padcev in the treatment of patients with locally advanced or metastatic urothelial cancer.
January 11th 2020
The Bladder Cancer Advocacy Network (BCAN) is pleased to announce two 2020 Young Investigator Awards (YIA), to support the development of outstanding early-career research scientists and clinical cancer research investigators.
January 11th 2020
This new option may save patients with high-risk non-muscle invasive bladder cancer from having to undergo a radical cystectomy to treat their disease.
January 10th 2020
At 15 years old the Bladder Cancer Advocacy Network looks back and takes a look ahead.
January 9th 2020
The Food and Drug Administration approved Keytruda for the treatment of patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer.
January 7th 2020
Patients with previously untreated locally advanced or metastatic urothelial carcinoma treated with Bavencio and best supportive care as a first-line maintenance therapy experienced significantly longer survival.
December 28th 2019
The Food and Drug Administration’s accelerated approval of Padcev offers patients with advanced bladder cancer a potential standard of care.
December 19th 2019
The Food and Drug Administration approved Padcev for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.
December 3rd 2019
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Keytruda (pembrolizumab), an anti-PD-1 immunotherapy, for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC), according to Merck, the drug’s manufacturer.
October 10th 2019
The IMvigor130 trial showed chemotherapy plus immunotherapy in patients with metastatic urothelial cancer could prolong the time to disease progression.
September 14th 2019
The oral medication Balversa (erdafitinib) shows promise in patients who have FGFR3 gene alterations.
July 22nd 2019
Genomic distinctions between bladder cancer variances are revealed through rapid autopsy, according to one study, and may help push forward bladder cancer research.